Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda

PHASE3CompletedINTERVENTIONAL

Enrollment

722

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

HIV Infections

Interventions

DRUG

Nevirapine

200 mg Nevirapine tablet

DRUG

HIV immune globulin solution

5% intravenous HIV immune globulin solution

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00639938 - Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda | Biotech Hunter | Biotech Hunter